KVUE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kenvue Inc (KVUE) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown modest financial growth and stability, the lack of positive trading signals, mixed analyst ratings, and limited upside potential make it a hold rather than a buy. The investor's funds might be better allocated to assets with clearer growth prospects or stronger buy signals.
The technical indicators for KVUE are mixed. The MACD is positive and expanding, suggesting bullish momentum. However, the RSI is neutral at 56.81, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 17.515), which could limit short-term upside potential.
The company's Q4 2025 financials show revenue growth of 3.22% YoY, net income growth of 12.63% YoY, and EPS growth of 13.33% YoY. Gross margin also improved slightly to 57.25%. Additionally, Johnson & Johnson's spin-off of its consumer health division (including Kenvue) has improved operational efficiency.
Analyst ratings are neutral to cautious, with recent price target reductions from Citi, Barclays, and UBS citing concerns over margin risks and input costs. The stock's bearish moving averages and limited upside potential (current price close to resistance levels) further dampen its attractiveness. Additionally, no significant hedge fund, insider, or congress trading activity has been reported.
In Q4 2025, Kenvue reported revenue of $3.78 billion, up 3.22% YoY. Net income increased to $330 million, up 12.63% YoY, and EPS rose to $0.17, up 13.33% YoY. Gross margin improved slightly to 57.25%, up 0.90% YoY. These results indicate modest growth and stability.
Analyst sentiment is neutral to cautious. Recent price target reductions from Citi, Barclays, and UBS reflect concerns over margin risks, input costs, and limited upside potential. The stock is rated Neutral or Hold by most analysts, with price targets ranging from $18 to $20, close to the current pre-market price of $17.46.
